Breast cancer is a multistep disease and infection with a DNA virus could play a role in one or more of the steps in this pathogenic process. High-risk human papillomaviruses (HPVs) are the causative agents of several cancers. In this study, we investigated HPV genotypes associated with breast cancer and its relationship with BRCA mutation for the detection of familial breast cancer. We analyzed 84 formalin-fixed, paraffin-embedded tissue blocks from 38 familial breast cancer and 46 nonfamilial breast cancer samples by multiplex polymerase chain reaction and clinical parameters. Overall prevalence of HPV infection was 27 of 84: 10 (37.03%) HPV-16, 9 (29.62%) HPV-18, 4 (14.81%) HPV-11, 1 (3.7%) HPV-31, 1 (3.7%) HPV-33, and 2 (7.4%) HPV35. Furthermore, 17 mtDNA4977 deletions and 5 5382insC mutations were detected from 38 familial breast cancer samples. Our results demonstrate that infection with HPV was prevalent among Iranian women with familial breast cancer and the testing of mtDNA4977 deletions and 5382insC mutations in combination with clinical parameters as major risk factors can serve in the identification of familial breast cancer.
Get full access to this article
View all access options for this article.
References
1.
ParkinDM, and BrayF. Chapter 2: The burden of HPV-related cancers. Vaccine, 2006; 24(Suppl 3):S11–S25.
2.
BoschFX, ManosMM, MunozN, ShermanM, JansenAM, PetoJ, SchiffmanMH, MorenoV, KurmanR, ShahKV, et al.Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst, 1995; 87:796–802.
3.
FormanD, de MartelC, LaceyCJ, SoerjomataramI, Lortet-TieulentJ, BruniL, VignatJ, FerlayJ, BrayF, PlummerM, FranceschiS.Global burden of human papillomavirus and related diseases. Vaccine, 2012, Suppl 5:F12–23.
4.
BurchellAN, WinerRL, SanjoséSD, and FrancoEL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine, 2006; 24:52–61.
5.
PharoahPD, DayNE, DuffyS, EastonDF, and PonderBA. Family history and the risk of breast cancer: A systematic review and meta-analysis. Int J Cancer, 1997; 71:800–809.
6.
FarshidG, BalleineRL, CummingsM, WaringP, and Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab). Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol, 2006; 30:1357–1366.
7.
RassiH, HoushmandM, HashemiM, MajidzadehK, and Hosseini AkbariMH. Investigation of mitochondrial common deletion and BRCA mutations for detection of familial breast cancers in archival breast cancer materials. Iran J Cancer Prev, 2009; 2:77–83.
8.
SmithJS, LindsayL, HootsB, KeysJ, FranceschiS, WinerR, and CliffordGM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer, 2007; 12:621–632.
9.
SotlarK, DiemerD, DethleffsA, HackY, StubnerA, VollmerN, Menton S MentonM, DietzK, WallwienerD, KandolfR, and BültmannB. Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol, 2004; 42:3176–3184.
10.
KarlsenF, KalantariK, JenkinsA, PettersenE, KristensenG, HolmR, JohanssonB, and HagmarB. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol, 1996; 34:2095–2100.
11.
SchiffmanM, WentzensenN, WacholderS, KinneyW, GageJC, and CastlePE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst, 2011; 103:368–383.
12.
SigaroodiA, NadjiSA, NaghshvarF, NateghR, EmamiH, and VelayatiAA. Human papillomavirus is associated with breast cancer in the north part of Iran. Scientific World Journal, 2012; 2012:837191.
13.
LiN, BiX, ZhangY, ZhaoP, ZhengT, and DaiM. Human papillomavirus infection and sporadic breast carcinoma risk: A meta-analysis. Breast Cancer Res Treat, 2011; 126:515–520.
14.
RassiH, SalehiB, MohammadianT, and Nahavandi AraghiA. Prevalence of human papillomavirus genotypes associated with cervical and breast cancers in Iran. Monoclon Antib Immunodiagn Immunother, 2013; 32:399–403.
15.
ZhuW, QinW, BradleyP, WesselA, PuckettCL, and SauterER. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis, 2005; 26:145–152.
16.
BansalC, PujaniM, SharmaKL, SrivastavaAN, SinghUS. Grading systems in the cytological diagnosis of breast cancer: a review. J Cancer Res Ther, 2014; 10(4):839–45.
17.
MikiY, SwensenJ, Shattuck-EidensD, FutrealPA, HarshmanK, TavtigianS, LuiQ, CochranC, BennettLM, DingW, BellR, RosenthalJ, HusseyC, TranT, McClureM, FryeC, HattierT, PhelpsR, Haugen-StranoA, KatcherH, YakumoK, GholamiZ, ShafferD, StoneS, BayerS, WrayC, BogdenR, DayananthP, WardJ, ToninP, NarodS, BristowPK, NorrisFH, HelveringL, MorrisonP, RosteckP, LaiM, BarrettJC, LewisC, NeuhausenS, Cannon-AlbrightL, GoldgarD, WisemanR, KambA, and SkolnickMH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994; 266:66–71.
18.
LakhaniSR, GustersonBA, JacquemierJ, SloaneJP, AndersonTJ, van de VijverMJ, VenterD, FreemanA, AntoniouA, McGuffogL, SmythE, SteelCM, HaitesN, ScottRJ, GoldgarD, NeuhausenS, DalyPA, OrmistonW, McManusR, ScherneckS, PonderBA, FutrealPA, PetoJ, Stoppa-LyonnetD, BignonYJ, and StrattonMR. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res, 2000; 6:782–789.
19.
WoosterR, BignellG, LancasterJ, SwiftS, SealS, MangionJ, CollinsN, GregoryS, GumbsC, and MicklemG. Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995; 378:789–792.
20.
KangD, and HamasakiN. Mitochondrial disease: Maintenance of mitochondrial genome and molecular diagnostics. Adv Clin Chem, 2006; 42:217–254.
21.
LiuY, ChenJJ, GaoQ, DalalS, HongY, MansurCP, BandV, and AndrophyEJ. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol, 1999; 73:7297–7307.
22.
ZhangY, FanS, MengQ, MaY, KatiyarP, SchlegelR, and RosenEM. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem, 2005; 280:33165–33177.
